Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Ductal Carcinoma in Situ, Breast Cancer
Interventions: Novel cavity marking technique; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Buffalo, New York + 4 more

Conditions: Invasive Ductal Breast Cancer, Carcinoma Breast Stage I
Interventions: Intraoperative Electron Radiotherapy; Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 95 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Diabetes, Healthy
Interventions: Mild pneumatic compression; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Non-Muscle Invasive Bladder Cancer
Interventions: Nadofaragene Firadenovec, Gemcitabine, Docetaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Baltimore, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Pregnancy - Prenatal Testing
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Heart Failure, CKD Stage 3
Interventions: AquaPass System; Device
Lead sponsor: AquaPass Medical Ltd.; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: La Jolla, California • San Francisco, California • Minneapolis, Minnesota + 5 more

Conditions: Scoliosis, Kyphosis
Interventions: Traditional technique, Minimally invasive technique; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Body Fat Disorder
Interventions: The ZELTIQ CoolSculpting System; Device
Lead sponsor: Zeltiq Aesthetics; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Ardmore, Pennsylvania

Conditions: Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Spondylolisthesis, Lumbar Spondylosis, Lumbar Radiculopathy, Lumbar Spine Instability, Synovial Cyst, Degenerative Disc Disease, Degenerative Spondylolisthesis, Degenerative Intervertebral Discs
Interventions: Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine, normal saline; Drug
Lead sponsor: John O'Toole; Other
Eligibility: 18 Years to 80 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Failure, Congestive
Interventions: Non-invasive central venous pressure; Device
Lead sponsor: Nihon Kohden; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions: Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine; Drug · Procedure · Biological + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 2,175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2038
U.S. locations: 999
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more

Conditions: Opioid-use Disorder, Chronic Pain
Interventions: Active Comparator: Active tDCS + Active TUS, Sham Comparator: Sham tDCS + Sham TUS; Device
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Hinsdale, Illinois • Cambridge, Massachusetts • Cleveland, Ohio

Conditions: Raynaud Phenomenon, Primary Raynaud Phenomenon, Raynaud Disease, Raynaud Syndrome
Interventions: gammaCore Sapphire, Sham Device; Device
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Deep Vein Thrombosis
Interventions: Mayo Dopplex ABIlity, Intermittent Pneumatic Compression (IPC); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Intracranial Pressure, Intracranial Pressure Changes
Interventions: CPMX3; Device
Lead sponsor: Compremium AG; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms, Breast
Interventions: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more

Conditions: Dry Eye Syndrome, Healthy
Interventions: Environmental Chamber Condition Change Intervention; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 89 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Dermatologic Diseases
Interventions: non-invasive sample collection of skin tissue; Other
Lead sponsor: DermTech; Other
Eligibility: 21 Years and older
Enrollment: 1,000 participants
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Denver, Colorado • Boca Raton, Florida

Conditions: Coronary Artery Stenosis
Interventions: FFR, IVUS, VH, or combination of the three; Procedure
Lead sponsor: Piedmont Healthcare; Other
Eligibility: 21 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions: Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent, Radical Cystectomy, Pelvic Lymphadenectomy, Stereotactic Body Radiation Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Transurethral Resection of Bladder Tumor, Cystoscopy, Biospecimen Collection, Questionnaire Administration; Radiation · Drug · Procedure + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Spinal Cord Injury
Interventions: LIFT System; Device
Lead sponsor: ONWARD Medical, Inc.; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Englewood, Colorado • Miami, Florida • Atlanta, Georgia + 6 more

Conditions: Parkinson's Disease
Interventions: TNM Device; Device
Lead sponsor: Scion NeuroStim; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: X-Linked Myotubular Myopathy
Interventions: ASP2957, Methylprednisolone, Prednisolone, Sirolimus; Genetic · Drug
Lead sponsor: Astellas Gene Therapies; Industry
Eligibility: Up to 36 Months · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Portland, Oregon + 1 more

Search by objective public record fields.

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)

Non-invasive Measurement of Microvascular Blood Flow During Mild External Compression of the Leg

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Informed Choice Regarding Invasive Prenatal Testing

Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System

Incidence of Proximal Junctional Kyphosis (PJK) in Long Posterior Spinal Fusion: A Study Comparing Traditional Open Surgery to Minimally Invasive Percutaneous Technique at the Proximal Fusion Levels

Fat Reduction in the Submandibular/Submental Area

Regional Anesthesia in Minimally Invasive Lumbar Spine Surgery

Comparison of Noninvasive vs. Invasive Hemodynamic Measurements

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Optimization of NIBS for Treatment of Addiction

Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.

Non-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression.

Non-invasive Intracranial Pressure Estimation by Measurement of the Occlusion Pressure of the Isolated Periorbital Vein

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Non-invasive Ocular Surface Measurements Before and After Interventions

A Sample Collection Study Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits

Validation of Stenosis Assessment by Coronary Artery Computed Tomography Against Invasive Measurements of Fractional Flow Reserve in Patients With Significant Coronary Artery Stenoses

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

The Up-LIFT Study of Non-Invasive ARC Therapy for Spinal Cord Injury

A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators